PDE5A and Alzheimer disease: MR results for both sexes were consistent with the main analysis (Figure S3), showing no association between genetically proxied PDE5 inhibition and AD risk (Male: scaled OR = 1.04, 95% CI = 0.97 to 1.11, p‐value = 0.3; Female: scaled OR = 0.95, 95% CI = 0.88–1.03, p‐value = 0.2).